Sign in

CIK 0001404644

  • Non-accelerated filer
  • Smaller reporting company

Neurogene Inc.

Sign in to watch
Ticker
NGNE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
980542593
Phone
+1 877-237-5020
Business address
535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY, 10011
Former names
Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, AQUINOX PHARMACEUTICALS (USA) INC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 38 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2018-03-15 MacKenzie Lloyd Chief Operating Officer Option exercise +1,302 $10.56 $14K 1,302
2018-03-15 MacKenzie Lloyd Chief Operating Officer Sale −1,302 $14.63 $19K 0
2018-03-15 MacKenzie Lloyd Chief Operating Officer Option exercise · Stock Option (Right to Buy) −1,302 0
2018-03-09 Troupin Barbara Chief Medical Officer Grant or award · Stock Option (Right to Buy) +75,000 75,000
2018-03-09 McCloskey Shelley VP, HR and Administration Grant or award · Stock Option (Right to Buy) +45,000 45,000
2018-03-09 Main David President and CEO Grant or award · Stock Option (Right to Buy) +225,000 225,000
2018-03-09 MacKenzie Lloyd Chief Operating Officer Grant or award · Stock Option (Right to Buy) +75,000 75,000
2018-03-09 Jenkins Abigail Chief Commercial Officer Grant or award · Stock Option (Right to Buy) +75,000 75,000
2018-03-09 Alam Kamran CFO, Vice President Finance Grant or award · Stock Option (Right to Buy) +75,000 75,000
2017-06-05 Main David President and CEO Option exercise +3,625 $9.60 $35K 75,155
2017-06-05 Main David President and CEO Sale −3,625 $13.16 $48K 71,530
2017-06-05 Main David President and CEO Option exercise · Stock Option (Right to Buy) −3,625 0
2017-06-02 Main David President and CEO Option exercise +6,000 $9.60 $58K 77,530
2017-06-02 Main David President and CEO Sale −6,000 $13.59 $82K 71,530
2017-06-02 Main David President and CEO Option exercise · Stock Option (Right to Buy( −6,000 3,625
2017-06-01 Main David President and CEO Option exercise +6,000 $9.60 $58K 77,530
2017-06-01 Main David President and CEO Sale −6,000 $13.00 $78K 71,530
2017-06-01 Main David President and CEO Option exercise · Stock Option (Right to Buy) −6,000 9,625
2017-05-08 SIMPSON TODD E Director Grant or award · Stock Option (Right to Buy) +9,000 9,000
2017-05-08 Nolan Sean P. Director Grant or award · Stock Option (Right to Buy) +9,000 9,000

Page 14 of 20 · 397 trades